Stay updated with the latest stock market news and insights
Trump ruled out nuclear weapons and ground troops in Iran as the U.S. weighs potential strikes using conventional bombs.
Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings and long-term wealth building ahead of the midterm elections.
Trump denied ordering Starlink restrictions in Ukraine as Zelenskyy warned that reduced connectivity disrupted military operations.
Brent crude closed at $109.86 as the U.S.-Iran and Russia-Ukraine wars keep squeezing global energy supplies, and drivers are paying for it at the pump.
Meta's earnings could test whether AI-driven ad growth justifies rising spending, putting QQQ, MAGS and FDN ETFs in focus as 2027 investment costs loom.
The iShares Semiconductor ETF is on a nine-session skid unseen since May 2006, South Korea's KOSPI just posted its worst week since 2008, optical names are falling like it's 2000, and Bank of America is hearing a Cisco echo.
BlackRock and State Street are challenging QQQ with lower-cost Nasdaq-100 ETFs, but J.P. Morgan data shows limited inflows and a wide trading-volume gap.
Shopify quietly raised prices on its Grow and Advanced plans, and JPMorgan thinks that could add $40 million a year. Here's the math, the AI cost problem, and why the stock still slid on Friday.
Palantir slides over 7% to $186.36 even as Jim Cramer sticks with his $250 call. Here's what's driving the selloff, the Goldman upgrade, and the key levels traders are watching.
Gasoline-only cars fell below half of global sales for the first time as Trump's fossil-fuel agenda diverges from the auto industry's electrification shift.
William Blair initiated coverage with an Outperform rating and a $31 price target, arguing investors have overlooked the China-focused cancer drug developer ahead of three pivotal trial results in 2027.
CoreWeave (CRWV) stock fell 20%, but JPMorgan says selloff fears are overblown. See why analyst Samik Chatterjee keeps an Overweight rating.
Charles Schwab (SCHW) posts record $7.17B revenue and a Q3 EPS beat, but funding costs and a smaller buyback have Wall Street revising its math.
William Blair initiates coverage with an Outperform rating and a $226 price target, betting Revolution Medicines' RAS(ON) platform can grow well beyond pancreatic cancer.
PayPal's new Glance partnership brings AI-powered product discovery, virtual try-ons and native checkout to more than 60 million mobile and TV devices.
